Találati lista | Tudóstér

001-es BibID:	BIBFORM112910
035-os BibID:	(wos)001011827700001 (scopus)85162693630
Első szerző:	Fuchs-Buder, Thomas
Cím:	Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents : The 2023 Geneva revision / Fuchs-Buder Thomas, Brull Sorin J., Fagerlund Malin Jonsson, Renew Ross J., Cammu Guy, Murphy Glenn S., Warlé Michiel, Vested Matias, Fülesdi Béla, Nemes Reka, Columb Malachy O., Damian Daniela, Davis Peter J., Iwasaki Haijme, Eriksson Lars I.
Dátum:	2023
ISSN:	0001-5172
Megjegyzések:	The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40, 59?74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51, 789?808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk depth of neuromuscular blockade neuromuscular monitoring neuromuscular research pharmacodynamics postoperative pulmonary complications time course of neuromuscular blockade
Megjelenés:	Acta Anaesthesiologica Scandinavica. - 67 : 8 (2023), p. 994-1017. -
További szerzők:	Brull, Sorin J. Fagerlund, Malin Jonsson Renew, J. Ross Cammu, Guy Murphy, Glenn S. Warlé, Michiel Vested, Matias Fülesdi Béla (1961-) (aneszteziológus) Nemes Réka (1985-) (aneszteziológus, intenzív terápiás szakorvos) Columb, Malachy O. Damian, Daniela Davis, Peter J. Iwasaki, Haijme Eriksson, Lars I.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM084535
Első szerző:	Fuchs-Buder, Thomas
Cím:	Residual neuromuscular blockade / Fuchs-Buder Thomas, Nemes Réka, Schmartz Denis
Dátum:	2016
ISSN:	0952-7907 1473-6500
Megjegyzések:	Purpose of review To revise the current literature on concepts for neuromuscular block management. Moreover, consequences of incomplete neuromuscular recovery on patients' postoperative pulmonary outcome are evaluated as well. Recent findings The incidence of residual paralysis may be as high as 70% and even small degrees of residual paralysis may have clinical consequences. Neostigmine should not be given before return of the fourth response of the train-of-four-stimulation and no more than 40?50mg/kg should be given. Sugammadex acts more rapidly and more predictably than neostigmine. Finally, there is convincing evidence in the literature that incomplete neuromuscular recovery may lead to a poor postoperative pulmonary outcome. Summary New evidence has emerged about the pathophysiological implications of incomplete neuromuscular recovery. Not only are the pulmonary muscles functionally impaired, but respiratory control is also affected. Residual paralysis endangers the coordination of the pharyngeal muscles and the integrity of the upper airway. However, neuromuscular monitoring and whenever needed pharmacological reversal prevent residual paralysis.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk neostigmine neuromuscular monitoring postoperative pulmonary outcome residual paralysis sugammadex
Megjelenés:	Current Opinion in Anaesthesiology. - 29 : 6 (2016), p. 662-667. -
További szerzők:	Nemes Réka (1985-) (aneszteziológus, intenzív terápiás szakorvos) Schmartz, Denis
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: